Applying Antisense Technology
- 1 December 2003
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1002 (1) , 244-251
- https://doi.org/10.1196/annals.1281.027
Abstract
Abstract: Progress in the development of antisense drugs over the last decade has led to the approval of the first such drug—Vitravene® for AIDS‐related CMV retinitis—and the development of a large number of antisense drugs in clinical trials. Antisense drugs are now being studied in Phase 3 trials for patients with cancer and inflammatory bowel disease. Other antisense drugs are in development for rheumatoid arthritis, other inflammatory conditions, and hepatitis C. Still other antisense drugs are entering clinical trials for treatment of metabolic conditions such as diabetes and hyperlipidemia. These latter applications provide the potential for target effects to be more directly measured in the clinic. Improved antisense chemistry, which will enhance the feasibility of subcutaneous and oral administration of antisense drugs and offer the potential of less frequent dosing, is expected to further expand the opportunities for antisense drug development.Keywords
This publication has 10 references indexed in Scilit:
- Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's diseaseGut, 2002
- Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-αThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced CancerJournal of Clinical Oncology, 1999
- A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseGastroenterology, 1998
- Differential role for protein kinase C-mediated signaling in the proliferation of medulloblastoma cell lines.International Journal of Oncology, 1998
- The Protein Kinase C Activator, Phorbol Ester, Elicits Disparate Functional Responses in Androgen-Sensitive and Androgen-Independent Human Prostatic Cancer CellsBiochemical and Biophysical Research Communications, 1998
- Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human FibroblastsPublished by Elsevier ,1996
- MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype.Journal of Clinical Investigation, 1995
- Involvement of the α Isoenzyme of Protein Kinase C in the Growth Inhibition Induced by Phorbol Esters in MH1C1 Hepatoma CellsBiochemical and Biophysical Research Communications, 1994
- Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.Proceedings of the National Academy of Sciences, 1994